As of 2023, the mortality rate for pancreas malignant neoplasms among women in the U.S. stood at 12.3 deaths per hundred thousand women. The forecasted data from 2024 to 2028 reveals a steady rate of 12.4 deaths per hundred thousand in 2024 and 2025, with a slight increase to 12.5 from 2026 onwards. This suggests a minimal increase in mortality, reflecting a CAGR close to zero across the 5-year period, indicative of stabilization rather than dramatic change.

Future trends to watch for include:

Advancements in treatment and early detection methods that could influence mortality rates.
Research into lifestyle factors and genetic predispositions that might impact the disease incidence and outcomes.
Healthcare policy changes affecting access to care, which could alter mortality figures.
Innovations in precision medicine that may alter individual patient outcomes over time.